Reports Q2 revenue $52.59M, consensus $54.77M. “We have witnessed accelerated growth of Fanapt revenue coinciding with the expansion of our sales efforts alongside a broad direct to consumer brand awareness campaign and we expect this trend to continue in the coming quarters,” said Mihael Polymeropoulos, CEO. “Significant regulatory and clinical milestones are expected in the coming months which have the potential to strengthen our commercial portfolio and advance our deep clinical pipeline.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Completes Key Study on Gastroparesis Treatment
- Vanda Pharmaceuticals (VNDA) Q2 Earnings Cheat Sheet
- Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies
- Vanda Pharmaceuticals doses first patient in trial of VCA-894A
- Vanda Approves Key Proposals at Annual Meeting